Literature DB >> 33428611

Estimating HIV pre-exposure prophylaxis need and impact in Malawi, Mozambique and Zambia: A geospatial and risk-based analysis.

Dominik Stelzle1,2, Peter Godfrey-Faussett3,4, Chuan Jia5, Obreniokibo Amiesimaka1, Mary Mahy3, Delivette Castor6, Ioannis Hodges-Mameletzis5, Lastone Chitembo7, Rachel Baggaley5, Shona Dalal5.   

Abstract

BACKGROUND: Pre-exposure prophylaxis (PrEP), a WHO-recommended HIV prevention method for people at high risk for acquiring HIV, is being increasingly implemented in many countries. Setting programmatic targets, particularly in generalised epidemics, could incorporate estimates of the size of the population likely to be eligible for PrEP using incidence-based thresholds. We estimated the proportion of men and women who would be eligible for PrEP and the number of HIV infections that could be averted in Malawi, Mozambique, and Zambia using prioritisation based on age, sex, geography, and markers of risk. METHODS AND
FINDINGS: We analysed the latest nationally representative Demographic and Health Surveys (DHS) of Malawi, Mozambique, and Zambia to determine the proportion of adults who report behavioural markers of risk for HIV infection. We used prevalence ratios (PRs) to quantify the association of these factors with HIV status. Using a multiplier method, we combined these proportions with the number of new HIV infections by district, derived from district-level modelled HIV estimates. Based on these numbers, different scenarios were analysed for the minimum number of person-years on PrEP needed to prevent 1 HIV infection (NNP). An estimated total of 38,000, 108,000, and 46,000 new infections occurred in Malawi, Mozambique, and Zambia in 2016, corresponding with incidence rates of 0.43, 0.63, and 0.57 per 100 person-years. In these countries, 9%-20% of new infections occurred among people with a sexually transmitted infection (STI) in the past 12 months and 40%-42% among people with either an STI or a non-regular sexual partner (NP) in the past 12 months (STINP). The models estimate that around 50% of new infections occurred in districts with incidence rates ≥1.0% in Mozambique and Zambia and ≥0.5% in Malawi. In Malawi, Mozambique, and Zambia, 35.1%, 21.9%, and 12.5% of the population live in these high-incidence districts. In the most parsimonious scenario, if women aged 15-34 years and men 20-34 years with an STI in the past 12 months living in high-incidence districts were to take PrEP, it would take a minimum of 65.8 person-years on PrEP to avert 1 HIV infection per year in Malawi, 35.2 in Mozambique, and 16.4 in Zambia. Our findings suggest that 3,300, 5,200, and 1,700 new infections could be averted per year in the 3 countries, respectively. Limitations of our study are that these values are based on modelled estimates of HIV incidence and self-reported behavioural risk factors from national surveys.
CONCLUSIONS: A large proportion of new HIV infections in these 3 African countries were estimated to occur among people who had either an STI or an NP in the past year, providing a straightforward means to set PrEP targets. Greater prioritisation of PrEP by district, sex, age, and behavioural risk factors resulted in lower NNPs thereby increasing PrEP cost-effectiveness, but also diminished the overall impact on reducing new infections.

Entities:  

Year:  2021        PMID: 33428611      PMCID: PMC7799816          DOI: 10.1371/journal.pmed.1003482

Source DB:  PubMed          Journal:  PLoS Med        ISSN: 1549-1277            Impact factor:   11.069


  23 in total

Review 1.  Epidemiology and prevention of sexually transmitted infections in men who have sex with men at risk of HIV.

Authors:  Eric P F Chow; Andrew E Grulich; Christopher K Fairley
Journal:  Lancet HIV       Date:  2019-04-18       Impact factor: 12.767

2.  Global PrEP roll-out: recommendations for programmatic success.

Authors:  K Rivet Amico; Linda-Gail Bekker
Journal:  Lancet HIV       Date:  2019-01-16       Impact factor: 12.767

3.  A Risk Assessment Tool for Identifying Pregnant and Postpartum Women Who May Benefit From Preexposure Prophylaxis.

Authors:  Jillian Pintye; Alison L Drake; John Kinuthia; Jennifer A Unger; Daniel Matemo; Renee A Heffron; Ruanne V Barnabas; Pamela Kohler; R Scott McClelland; Grace John-Stewart
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

4.  Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.

Authors:  Jean-Michel Molina; Isabelle Charreau; Bruno Spire; Laurent Cotte; Julie Chas; Catherine Capitant; Cecile Tremblay; Daniela Rojas-Castro; Eric Cua; Armelle Pasquet; Camille Bernaud; Claire Pintado; Constance Delaugerre; Luis Sagaon-Teyssier; Soizic Le Mestre; Christian Chidiac; Gilles Pialoux; Diane Ponscarme; Julien Fonsart; David Thompson; Mark A Wainberg; Veronique Doré; Laurence Meyer
Journal:  Lancet HIV       Date:  2017-07-23       Impact factor: 12.767

5.  The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.

Authors:  Ide Cremin; Ramzi Alsallaq; Mark Dybul; Peter Piot; Geoffrey Garnett; Timothy B Hallett
Journal:  AIDS       Date:  2013-01-28       Impact factor: 4.177

6.  HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.

Authors: 
Journal:  Lancet       Date:  2019-06-13       Impact factor: 79.321

7.  Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017.

Authors:  Laura Dwyer-Lindgren; Michael A Cork; Amber Sligar; Krista M Steuben; Kate F Wilson; Naomi R Provost; Benjamin K Mayala; John D VanderHeide; Michael L Collison; Jason B Hall; Molly H Biehl; Austin Carter; Tahvi Frank; Dirk Douwes-Schultz; Roy Burstein; Daniel C Casey; Aniruddha Deshpande; Lucas Earl; Charbel El Bcheraoui; Tamer H Farag; Nathaniel J Henry; Damaris Kinyoki; Laurie B Marczak; Molly R Nixon; Aaron Osgood-Zimmerman; David Pigott; Robert C Reiner; Jennifer M Ross; Lauren E Schaeffer; David L Smith; Nicole Davis Weaver; Kirsten E Wiens; Jeffrey W Eaton; Jessica E Justman; Alex Opio; Benn Sartorius; Frank Tanser; Njeri Wabiri; Peter Piot; Christopher J L Murray; Simon I Hay
Journal:  Nature       Date:  2019-05-15       Impact factor: 49.962

8.  Innovations in Human Immunodeficiency Virus (HIV) Care Delivery During the Coronavirus Disease 2019 (COVID-19) Pandemic: Policies to Strengthen the Ending the Epidemic Initiative-A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.

Authors:  Wendy S Armstrong; Allison L Agwu; Ernie-Paul Barrette; Rachel Bender Ignacio; Jennifer J Chang; Jonathan A Colasanti; Michelle Floris-Moore; Marwan Haddad; Lynsay MacLaren; Andrea Weddle
Journal:  Clin Infect Dis       Date:  2021-01-23       Impact factor: 9.079

9.  Heterogeneity of HIV incidence: a comparative analysis between fishing communities and in a neighbouring rural general population, Uganda, and implications for HIV control.

Authors:  A Kamali; R N Nsubuga; E Ruzagira; U Bahemuka; G Asiki; M A Price; R Newton; P Kaleebu; P Fast
Journal:  Sex Transm Infect       Date:  2016-03-01       Impact factor: 3.519

10.  Highlights of AIDS 2020.

Authors:  Philippa Harris
Journal:  Lancet HIV       Date:  2020-08       Impact factor: 12.767

View more
  2 in total

1.  Awareness of and Preferences for Preexposure Prophylaxis (PrEP) among MSM at High Risk of HIV Infection in Southern China: Findings from the T2T Study.

Authors:  Weiying Chen; Yi Ding; Jianghao Chen; Peipei Zhao; Zhenyu Wang; Xiaojun Meng; Tianjian Jia; Heping Zheng; Bin Yang; Zhenzhou Luo; Huachun Zou
Journal:  Biomed Res Int       Date:  2021-04-02       Impact factor: 3.411

2.  HIV prevention for the next decade: Appropriate, person-centred, prioritised, effective, combination prevention.

Authors:  Peter Godfrey-Faussett; Luisa Frescura; Quarraisha Abdool Karim; Michaela Clayton; Peter D Ghys
Journal:  PLoS Med       Date:  2022-09-26       Impact factor: 11.613

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.